Research Roundup

Debbie Rigby rounds up the latest in research news Reduction in Use of Risperidone for Dementia in Australia Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the TGA amended the indication to restrict use in BPSD to patients with Alzheimer’s

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous GPs, practice staff value community pharmacy ‘safety net’
Next We're back